Seven oncology approvals included nods for subcutaneous Rybrevant and Lunsumio.
ApexOnco Front Page
Recent articles
The company hands its PD-L1 x VEGF bispecific back to ImmuneOnco.
No fewer than four ADCs with this target start human testing.
On a cross-trial basis varegacestat beats Ogsiveo.
The group will start a pivotal trial of samuraciclib following promising second-line results.
Lilly reveals that an Inluriyo/Verzenio combo is being limited to ESR1-mutant disease.
Some time ago Opdivo beat Adcetris in an NCI trial, and now Bristol files.
Arcus steps back from TIGIT as its Fc-silent claim crumbles.
